Beijing Jiake Ruikang Pharmaceutical Technology

Beijing Jacoray Pharmaceutical Technology (Jacoray) is a clinical-stage biotechnology company focused on the research and development of novel therapies for cardiovascular and metabolic diseases. Originally established as a subsidiary of Jacobio Pharmaceuticals to house its early-stage cardiovascular programs, Jacoray was spun out in October 2025 when Oceanpine Capital acquired an 80% majority stake in the company for RMB 200 million. The company's lead program is JAR-2203, an investigational small interfering RNA (siRNA) therapeutic targeting apolipoprotein(a) (LPA) for the treatment of hyperlipoproteinemia(a). In July 2026, JAR-2203 received Investigational New Drug (IND) clearance from China's National Medical Products Administration (NMPA) to initiate Phase I clinical trials. Jacoray leverages advanced RNA interference technologies to develop highly targeted, disease-modifying treatments for high-value cardiovascular risk factors.